focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShire Regulatory News (SHP)

  • There is currently no data for SHP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - SHIRE PLC

27 Dec 2018 12:39

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser: Barclays PLC.
(b) Owner or controller of interest and short
positions disclosed, if different from 1(a):
(c) Name of offeror/offeree in relation to whose SHIRE PLC
relevant securities this form relates:
(d) If an exempt fund manager connected with an
offeror/offeree, state this and specify identity of
offeror/offeree:
(e) Date position held/dealing undertaken: 26 December 2018
(f) In addition to the company in 1(c) above, is the discloser making YES:
disclosures in respect of any other party to the offer? TAKEDA PHARMACEUTICAL CO LTD

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security: 5p ordinary
Interests Short Positions
Number (%) Number (%)
(1) Relevant securities owned
and/or controlled: 8,055,321 0.88% 989,183 0.11%
(2) Cash-settled derivatives:
216,885 0.02% 5,450,073 0.59%
(3) Stock-settled derivatives (including options)
and agreements to purchase/sell: 755,400 0.08% 570,800 0.06%
(4)
TOTAL: 9,027,606 0.98% 7,010,056 0.76%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant Purchase/sale Number of Price per unit
security securities
ADR Purchase 2 174.4600 USD
ADR Purchase 30 174.1200 USD
ADR Purchase 100 172.1600 USD
ADR Purchase 100 172.8000 USD
ADR Purchase 100 173.0000 USD
ADR Purchase 100 172.2400 USD
ADR Purchase 100 173.9000 USD
ADR Purchase 100 173.2900 USD
ADR Purchase 180 172.0000 USD
ADR Purchase 200 172.6900 USD
ADR Purchase 200 171.9400 USD
ADR Purchase 300 172.4266 USD
ADR Purchase 301 172.7137 USD
ADR Purchase 378 171.8362 USD
ADR Purchase 400 173.6737 USD
ADR Purchase 440 172.3139 USD
ADR Purchase 480 172.1104 USD
ADR Purchase 500 172.8518 USD
ADR Purchase 500 173.9380 USD
ADR Purchase 600 171.9900 USD
ADR Purchase 800 173.9425 USD
ADR Purchase 1,100 172.4931 USD
ADR Purchase 1,200 173.3075 USD
ADR Purchase 1,600 172.8079 USD
ADR Purchase 2,000 171.3000 USD
ADR Purchase 2,400 173.0056 USD
ADR Purchase 2,509 173.3694 USD
ADR Purchase 2,700 172.7616 USD
ADR Purchase 3,500 173.6897 USD
ADR Purchase 4,500 173.2266 USD
ADR Purchase 4,966 173.0044 USD
ADR Sale 2 174.4600 USD
ADR Sale 78 171.9115 USD
ADR Sale 100 173.3800 USD
ADR Sale 100 173.2900 USD
ADR Sale 100 173.1900 USD
ADR Sale 100 172.8300 USD
ADR Sale 100 174.8400 USD
ADR Sale 100 171.9000 USD
ADR Sale 100 171.5500 USD
ADR Sale 100 172.6400 USD
ADR Sale 100 174.7150 USD
ADR Sale 100 174.3800 USD
ADR Sale 100 174.6150 USD
ADR Sale 137 173.7352 USD
ADR Sale 160 174.3700 USD
ADR Sale 200 171.9500 USD
ADR Sale 200 174.3100 USD
ADR Sale 200 174.9350 USD
ADR Sale 230 172.8765 USD
ADR Sale 247 174.8312 USD
ADR Sale 300 173.3300 USD
ADR Sale 300 174.7866 USD
ADR Sale 300 173.5833 USD
ADR Sale 300 173.3233 USD
ADR Sale 300 173.2058 USD
ADR Sale 300 172.5483 USD
ADR Sale 400 174.8025 USD
ADR Sale 410 174.9000 USD
ADR Sale 500 173.2100 USD
ADR Sale 662 174.5161 USD
ADR Sale 772 173.4233 USD
ADR Sale 800 172.4725 USD
ADR Sale 1,100 173.3604 USD
ADR Sale 1,100 174.2500 USD
ADR Sale 1,700 172.9332 USD
ADR Sale 2,000 171.3000 USD
ADR Sale 2,400 172.1735 USD
ADR Sale 2,509 173.3694 USD
ADR Sale 3,100 173.7066 USD
ADR Sale 4,500 173.1950 USD
ADR Sale 7,200 173.1798 USD
ADR Sale 27,869 174.1124 USD

(b) Cash-settled derivative transactions

Class of relevant security Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities Price per unit

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class Product Writing, Number Exercise Type Expiry Option
of description purchasing, of price date money
relevant selling, securities per unit paid/
security varying etc to which received
option per unit
relates
ADR Call Options Purchasing 4,500 175 USD American 18 Jan 2019 3.6233 USD
ADR Call Options Selling 4,500 170 USD American 18 Jan 2019 6.5677 USD
ADR Put Options Selling 10,000 165 USD American 18 Jan 2019 1.5000 USD

(ii) Exercise

Class of relevant security Product description

e.g. call option

Exercising/ exercised against Number of securities Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing

e.g. subscription, conversion

Details Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached? YES
Date of disclosure: 27 Dec 2018
Contact name: Large Holdings Regulatory Operations
Telephone number: 020 3134 7213

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

SUPPLEMENTAL FORM 8 (OPEN POSITIONS)

DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL ETC.

Note 5(i) on Rule 8 of the Takeover Code (the “Code”)

1. KEY INFORMATION

Identity of the person whose positions/dealings Barclays PLC.
are being disclosed:
Name of offeror/offeree in relation to whose SHIRE PLC
relevant securities this from relates:

2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)

Class Product Writing, Number Exercise Type Expiry
of description purchasing, of price date
relevant selling, securities per unit
security varying etc to which
option
relates
ADR Call Options Purchased 100 220.0000 American 18 Jan 2019
ADR Call Options Purchased 100 105.0000 American 18 Jan 2019
ADR Call Options Purchased 100 140.0000 American 18 Jan 2019
ADR Call Options Purchased 100 155.0000 American 15 Jan 2021
ADR Call Options Purchased 100 195.0000 American 19 Jul 2019
ADR Call Options Purchased 100 195.0000 American 15 Jan 2021
ADR Call Options Purchased 100 190.0000 American 4 Jan 2019
ADR Call Options Purchased 100 110.0000 American 17 Jan 2020
ADR Call Options Purchased 100 173.0000 American 18 Jan 2019
ADR Call Options Purchased 200 130.0000 American 17 Jan 2020
ADR Call Options Purchased 200 135.0000 American 17 Jan 2020
ADR Call Options Purchased 200 155.0000 American 17 Jan 2020
ADR Call Options Purchased 200 160.0000 American 17 Jan 2020
ADR Call Options Purchased 200 210.0000 American 18 Jan 2019
ADR Call Options Purchased 200 120.0000 American 17 Jan 2020
ADR Call Options Purchased 300 115.0000 American 18 Jan 2019
ADR Call Options Purchased 400 170.0000 American 17 Jan 2020
ADR Call Options Purchased 400 230.0000 American 18 Jan 2019
ADR Call Options Purchased 500 150.0000 American 18 Jan 2019
ADR Call Options Purchased 500 180.0000 American 18 Apr 2019
ADR Call Options Purchased 600 173.0000 American 28 Dec 2018
ADR Call Options Purchased 700 175.0000 American 28 Dec 2018
ADR Call Options Purchased 900 195.0000 American 18 Apr 2019
ADR Call Options Purchased 1,000 170.0000 American 19 Jul 2019
ADR Call Options Purchased 1,000 175.0000 American 19 Jul 2019
ADR Call Options Purchased 1,000 185.0000 American 19 Jul 2019
ADR Call Options Purchased 1,000 180.0000 American 17 Jan 2020
ADR Call Options Purchased 1,000 135.0000 American 18 Jan 2019
ADR Call Options Purchased 1,000 190.0000 American 11 Jan 2019
ADR Call Options Purchased 1,400 230.0000 American 15 Jan 2021
ADR Call Options Purchased 1,700 195.0000 American 17 Jan 2020
ADR Call Options Purchased 2,000 165.0000 American 18 Apr 2019
ADR Call Options Purchased 2,000 150.0000 American 17 Jan 2020
ADR Call Options Purchased 2,100 190.0000 American 18 Apr 2019
ADR Call Options Purchased 2,600 185.0000 American 18 Apr 2019
ADR Call Options Purchased 3,100 155.0000 American 18 Jan 2019
ADR Call Options Purchased 3,600 175.0000 American 18 Apr 2019
ADR Call Options Purchased 3,800 125.0000 American 18 Jan 2019
ADR Call Options Purchased 4,300 170.0000 American 18 Apr 2019
ADR Call Options Purchased 5,700 160.0000 American 19 Jul 2019
ADR Call Options Purchased 7,700 155.0000 American 18 Apr 2019
ADR Call Options Purchased 9,200 200.0000 American 15 Jan 2021
ADR Call Options Purchased 17,100 175.0000 American 18 Jan 2019
ADR Call Options Purchased 18,200 160.0000 American 18 Jan 2019
ADR Call Options Purchased 22,300 200.0000 American 18 Jan 2019
ADR Call Options Purchased 23,900 195.0000 American 18 Jan 2019
ADR Call Options Purchased 137,900 190.0000 American 18 Jan 2019
ADR Call Options Written -56,000 200.0000 American 17 Jan 2020
ADR Call Options Written -42,400 200.0000 American 19 Jul 2019
ADR Call Options Written -33,100 185.0000 American 18 Jan 2019
ADR Call Options Written -31,000 180.0000 American 18 Jan 2019
ADR Call Options Written -7,400 240.0000 American 17 Jan 2020
ADR Call Options Written -4,200 165.0000 American 18 Jan 2019
ADR Call Options Written -2,700 145.0000 American 18 Jan 2019
ADR Call Options Written -2,400 130.0000 American 18 Jan 2019
ADR Call Options Written -1,500 210.0000 American 19 Jul 2019
ADR Call Options Written -1,000 85.0000 American 18 Jan 2019
ADR Call Options Written -800 155.0000 American 18 Apr 2019
ADR Call Options Written -800 170.0000 American 18 Jan 2019
ADR Call Options Written -700 163.0000 American 28 Dec 2018
ADR Call Options Written -600 160.0000 American 18 Jan 2019
ADR Call Options Written -500 135.0000 American 19 Jul 2019
ADR Call Options Written -300 160.0000 American 18 Apr 2019
ADR Call Options Written -100 140.0000 American 17 Jan 2020
ADR Call Options Written -100 150.0000 American 18 Apr 2019
ADR Put Options Purchased -267,200 165.0000 American 18 Jan 2019
ADR Put Options Purchased -41,400 135.0000 American 18 Jan 2019
ADR Put Options Purchased -15,600 160.0000 American 18 Apr 2019
ADR Put Options Purchased -5,900 180.0000 American 18 Jan 2019
ADR Put Options Purchased -5,300 165.0000 American 15 Jan 2021
ADR Put Options Purchased -5,000 170.0000 American 18 Jan 2019
ADR Put Options Purchased -4,200 155.0000 American 18 Jan 2019
ADR Put Options Purchased -3,700 145.0000 American 17 Jan 2020
ADR Put Options Purchased -3,500 140.0000 American 18 Jan 2019
ADR Put Options Purchased -2,900 175.0000 American 18 Jan 2019
ADR Put Options Purchased -2,700 80.0000 American 18 Jan 2019
ADR Put Options Purchased -2,600 160.0000 American 15 Jan 2021
ADR Put Options Purchased -2,500 120.0000 American 17 Jan 2020
ADR Put Options Purchased -2,300 85.0000 American 18 Jan 2019
ADR Put Options Purchased -2,300 175.0000 American 4 Jan 2019
ADR Put Options Purchased -2,100 150.0000 American 18 Jan 2019
ADR Put Options Purchased -2,000 130.0000 American 15 Jan 2021
ADR Put Options Purchased -2,000 80.0000 American 17 Jan 2020
ADR Put Options Purchased -1,800 115.0000 American 18 Jan 2019
ADR Put Options Purchased -1,700 160.0000 American 17 Jan 2020
ADR Put Options Purchased -1,400 165.0000 American 17 Jan 2020
ADR Put Options Purchased -1,200 135.0000 American 17 Jan 2020
ADR Put Options Purchased -1,100 170.0000 American 17 Jan 2020
ADR Put Options Purchased -1,100 70.0000 American 17 Jan 2020
ADR Put Options Purchased -1,000 155.0000 American 15 Jan 2021
ADR Put Options Purchased -800 150.0000 American 17 Jan 2020
ADR Put Options Purchased -600 180.0000 American 18 Apr 2019
ADR Put Options Purchased -500 140.0000 American 17 Jan 2020
ADR Put Options Purchased -400 165.0000 American 19 Jul 2019
ADR Put Options Purchased -200 65.0000 American 17 Jan 2020
ADR Put Options Purchased -100 75.0000 American 17 Jan 2020
ADR Put Options Purchased -100 195.0000 American 15 Jan 2021
ADR Put Options Written 100 95.0000 American 18 Jan 2019
ADR Put Options Written 100 110.0000 American 18 Jan 2019
ADR Put Options Written 100 110.0000 American 17 Jan 2020
ADR Put Options Written 200 200.0000 American 17 Jan 2020
ADR Put Options Written 200 100.0000 American 18 Jan 2019
ADR Put Options Written 1,000 90.0000 American 18 Jan 2019
ADR Put Options Written 1,000 147.0000 American 28 Dec 2018
ADR Put Options Written 1,800 185.0000 American 18 Jan 2019
ADR Put Options Written 2,300 130.0000 American 18 Jan 2019
ADR Put Options Written 4,000 165.0000 American 18 Apr 2019
ADR Put Options Written 5,300 120.0000 American 18 Jan 2019
ADR Put Options Written 6,900 170.0000 American 18 Apr 2019
ADR Put Options Written 11,000 160.0000 American 19 Jul 2019
ADR Put Options Written 13,800 155.0000 American 18 Apr 2019
ADR Put Options Written 19,900 165.0000 American 18 Jan 2019
ADR Put Options Written 29,300 125.0000 American 18 Jan 2019
ADR Put Options Written 89,500 160.0000 American 18 Jan 2019
ADR Put Options Written 287,900 145.0000 American 18 Jan 2019

3. AGREEMENTS TO PURCHASE OR SELL ETC.

Full details should be given so that the nature of the interest or position can be fully understood:

It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to cash-settled derivatives.

The currency of all prices and other monetary amounts should be stated.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181227005181/en/

Copyright Business Wire 2018

Date   Source Headline
8th Jan 20195:30 pmGNWDirector/PDMR Shareholding
8th Jan 20193:20 pmRNSForm 8.3 - Shire plc
8th Jan 20193:19 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
8th Jan 20193:13 pmRNSForm 8.3 - Shire plc
8th Jan 20193:07 pmRNSForm 8.5 (EPT/NON-RI)
8th Jan 20192:28 pmRNSForm 8.5 (EPT/RI) - Replacement of Shire
8th Jan 20192:23 pmRNSForm 8.5 (EPT/RI) - Replacement of Shire
8th Jan 20192:21 pmRNSForm 8.5 (EPT/RI) - Replacement of Shire
8th Jan 20191:57 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
8th Jan 20191:27 pmRNSForm 8.3 - Shire plc
8th Jan 201912:31 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
8th Jan 201912:29 pmRNSForm 8.3 - Takeda Pharmaceutical
8th Jan 201912:27 pmRNSForm 8.3 - Shire plc
8th Jan 201911:42 amRNSForm 8.5 (EPT/NON-RI)
8th Jan 201911:33 amRNSForm 8.5 (EPT/NON-RI)- Shire Plc
8th Jan 201910:49 amRNSForm 8.5 (EPT/RI)
8th Jan 201910:41 amRNSForm 8.3 - Takeda Pharmaceutical Company Limited
8th Jan 201910:26 amRNSForm 8.5 (EPT/RI)- Shire plc
8th Jan 20199:51 amRNSForm 8.3 - Shire Plc
8th Jan 20198:44 amRNSForm 8.5 (EPT/RI) - SHIRE PLC
8th Jan 20197:00 amRNSForm 8.3 - Takeda Pharmaceutical Company Limited
8th Jan 20197:00 amGNWScheme becomes effective
7th Jan 20195:00 pmGNWHolding(s) in Company
7th Jan 20193:42 pmRNSForm 8.5 (EPT/RI) - Amendment
7th Jan 20193:20 pmRNSForm 8.3 - Shire plc
7th Jan 20193:02 pmRNSForm 8.3 - Shire plc
7th Jan 20193:00 pmRNSForm 8.5 (EPT/NON-RI)
7th Jan 20193:00 pmRNSForm 8.3 - Shire plc
7th Jan 20192:59 pmRNSForm 8.3 - Takeda Pharmaceutical
7th Jan 20192:50 pmPRNForm 8.3 - Shire Plc
7th Jan 20192:49 pmRNSForm 8.3 - Shire plc
7th Jan 20192:47 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
7th Jan 20192:45 pmBUSForm 8.3 - Shire plc
7th Jan 20191:55 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
7th Jan 20191:54 pmRNSForm 8.3 - Shire plc
7th Jan 20191:39 pmRNSForm 8.3 - [Shire Plc]
7th Jan 20191:32 pmRNSForm 8.5 (EPT/RI) - Replacement of Shire
7th Jan 20191:29 pmRNSForm 8.5 (EPT/RI) - Replacement of Shire
7th Jan 201912:57 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
7th Jan 201912:56 pmRNSForm 8.3 - Shire plc
7th Jan 201912:42 pmRNSForm 8.5 (EPT/NON-RI)
7th Jan 201911:52 amRNSForm 8.3 - Takeda Pharmaceutical Company Limited
7th Jan 201911:43 amBUSForm 8.3 - SHIRE PLC
7th Jan 201911:30 amRNSForm 8.3 - Takeda Pharmaceutical Company Limited
7th Jan 201911:27 amRNSForm 8.3 - Shire plc
7th Jan 201911:01 amRNSForm 8.5 (EPT/RI)- Shire plc
7th Jan 201910:59 amRNSForm 8.5 (EPT/NON-RI)- Shire Plc
7th Jan 201910:35 amRNSForm 8.5 - Shire plc
7th Jan 201910:16 amRNSForm 8.5 (EPT/RI) - SHIRE PLC
7th Jan 201910:13 amRNSForm 8.5 (EPT/RI) - Amendment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.